Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03820102
Other study ID # IR,VitD in HCV
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 2019
Est. completion date October 2019

Study information

Verified date February 2019
Source Assiut University
Contact Mohamed H Abdelgawad, specialist
Phone 01008778754
Email d_m_h_80@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. Study Changes in lipid profile and the impact of Insulin resistance on virological response in patients with Hepatitis C viral infection treated by Direct Acting Antiviral agents

2. The assessment of serum vitamin D levels in HCV infected patients and predictive value of pre-treatment serum vitamin D level for achieving sustained virological response at 12 weeks post-treatment


Description:

Patients and methods:

This cross-sectional study will include 100patients of chronic HCV infection who attend El Raghy Assiut university Hospital, either inpatients or outpatients. Chronic HCV infection will be diagnosed based on detectable HCV RNA with anti-HCV Ab in patient with clinical and/or ultrasonographic criteria of chronic liver disease.

Patients will receive treatment to HCV by DAAs and follow up for 12 weeks to confirm sustained virological response

Method:

Patients presenting in this study will be subjected to the following:

1. Full history and clinical evaluation.

2. Body weight (kg) and height (m).

3. BMI will calculate as weight divided by squared height (kg/m2).

4. Waist circumference will measured at a level midway between the lowest rib and the iliac crest, and the hip circumference at the level of the great trochanters, with the legs close together.

5. Blood pressure (mmHg) was measured twice in the upper arm after a 10-min period of rest and taken an average.

Laboratory investigations will include:

- Complete blood count (CBC)

- Liver function test

- HCV Ab and HCV RNA by PCR

- HBs Ag

- Alpha fetoprotein

- Lipid profile

- Serum urea and creatinine

- Fasting blood sugar (FBG)and Serum fasting insulin level

- Insulin resistance determined via Homeostasis Model Assessment (HOMA-IR) IR = fasting insulin (µu/ml) × fasting glucose (mmol/L) ----------------------------------------------------------------- 22.5 An index value of ˃ 2. 5 was defined as IR (Huang et al., 2011)

- Vitamin D level:

Vitamin D deficiency wasdefined as a 25 (OH)-vitamin D serum level < 20 ng/mL, vitaminD insufficiency as 25 (OH)-vitamin D levels of 20 - 29.9ng/mL, and normal vitamin D levels ≥ 30 ng/mL (Holick MF et al.,2011)

- Abdominal Ultrasound

- Electrocardiogram (ECG)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date October 2019
Est. primary completion date September 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chronic HCV will receive DAAs for treatment

Exclusion Criteria:

1. Decompensated liver cirrhosis, hepatocellular carcinoma, history of liver transplant

2. Co-existing liver disease (hepatitis B virus, autoimmune hepatitis, human immunodeficiency virus)

3. Extra-hepatic malignancy except after two years of disease free interval.

4. Patients with diabetes mellitus.

5. Patients with Chronic kidney disease.

6. Pregnancy or in ability to use effective contraception.

7. Patients with history of using lipid lowering therapy

8. relapser or failure of previous HCV treatment

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

Janovy J Jr. Problems in the comparative physiology of some trypanosomatid flagellates. Acta Trop. 1977 Jun;34(2):177-84. — View Citation

Ramachandran N, Colman RF. Evidence for a critical glutamyl and an aspartyl residue in the function of pig heart diphosphopyridine nucleotide dependent isocitrate dehydrogenase. Biochemistry. 1977 Apr 19;16(8):1564-73. — View Citation

Selhub J, Rosenberg IH. Demonstration of high-affinity folate binding activity associated with the brush border membranes of rat kidney. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3090-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary SVR12 sustained virological response 12 week after treatment 12 week after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05942937 - National Prisons Hepatitis Education Project: Research Evaluation N/A
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Recruiting NCT05794646 - Community Intervention to Eliminate HCV Among People Who Use Drugs. N/A
Completed NCT04971330 - Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A
Active, not recruiting NCT03981445 - Integrated HIV Prevention and HCV Care for PWID N/A
Completed NCT02452814 - Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection N/A
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Not yet recruiting NCT06316739 - The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City N/A
Completed NCT02116543 - TD-6450 MAD Study in HCV Infected Subjects Phase 1
Recruiting NCT05454579 - The South-East Asian Transgender Health Cohort
Active, not recruiting NCT03221309 - Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Completed NCT03801707 - Utilization of Hepatitis C Positive Kidneys in Negative Recipients Phase 2/Phase 3
Completed NCT01074008 - A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Phase 2
Completed NCT05616598 - Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Phase 2/Phase 3
Recruiting NCT05854511 - Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Phase 3
Completed NCT03069001 - Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV Phase 4
Completed NCT01842451 - A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C Phase 2